# EDGAR Filing Document

**Accession Number:** 0001818331
**File Stem:** 0001818331-25-000105
**Filing Date:** 2025-7
**Character Count:** 41760
**Document Hash:** 678c326b285f719802fe9f125235416a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001818331-25-000105.hdr.sgml**: 20250729

**ACCESSION NUMBER**: 0001818331-25-000105

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 31

**CONFORMED PERIOD OF REPORT**: 20250729

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250729

**DATE AS OF CHANGE**: 20250729

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GeneDx Holdings Corp.
- **CENTRAL INDEX KEY:** 0001818331
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HEALTH SERVICES [8000]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 851966622
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39482
- **FILM NUMBER:** 251157542

**BUSINESS ADDRESS:**
- **STREET 1:** 333 LUDLOW STREET
- **STREET 2:** NORTH TOWER, 6TH FLOOR
- **CITY:** STAMFORD
- **STATE:** CT
- **ZIP:** 06902
- **BUSINESS PHONE:** 888-729-1206

**MAIL ADDRESS:**
- **STREET 1:** 333 LUDLOW STREET
- **STREET 2:** NORTH TOWER, 6TH FLOOR
- **CITY:** STAMFORD
- **STATE:** CT
- **ZIP:** 06902

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sema4 Holdings Corp.
- **DATE OF NAME CHANGE:** 20210721

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CM Life Sciences, Inc.
- **DATE OF NAME CHANGE:** 20200715

?xml version='1.0' encoding='ASCII'? wgs-20250729

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): July 29, 2025

**Commission file number 001-39482**

![Blue Logo 600x208.jpg](wgs-20250729_g1.jpg)

**GeneDx Holdings Corp.** 

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **85-1966622** |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| **333 Ludlow Street, North Tower; 6th Floor** <br>**Stamford, Connecticut 06902** | **333 Ludlow Street, North Tower; 6th Floor** <br>**Stamford, Connecticut 06902** |
| (Address of Principal Executive Offices) (Zip Code) | (Address of Principal Executive Offices) (Zip Code) |

---

Registrant's telephone number, including area code: **(888) 729-1206** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:** 

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Class A common stock, par value $0.0001 per share | WGS | The Nasdaq Stock Market LLC |
| Warrants to purchase one share of Class A common stock, each at an exercise price of $379.50 per share | WGSWW | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Results of Operations and Financial Condition.**

On July 29, 2025, GeneDx Holdings Corp. (the "Company") issued a press release (the "Press Release") and will hold a conference call announcing the Company's financial results for the quarter ended June 30, 2025. Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.

The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Financial Statements and Exhibits.**

**(d) Exhibits**

---

| | |
|:---|:---|
| **<u>Exhibit No</u>** | **<u>Description</u>** |
| 99.1 | <u>[Press Release, dated July 29, 2025, regarding the registrant's results for the quarter ended June 30, 2025](q22025pressrelease.htm)</u> |
| 99.2 | <u>[Earnings Presentation, dated July 29, 2025](finalq2earningspresentat.htm)</u> |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | **GENEDX HOLDINGS CORP.** | **GENEDX HOLDINGS CORP.** |
| Date: | July 29, 2025 | By: | /s/ Katherine Stueland |
|  |  | Name: | Katherine Stueland |
|  |  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![bluelogo600x208.jpg](bluelogo600x208.jpg)

**GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Reported second quarter 2025 revenues of $102.7 million with 69% year-over-year growth of exome and genome test revenue** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Expanded adjusted gross margin to 71% and generated adjusted net income**<sup>1</sup> **of $15.0 million for the second quarter 2025**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Raised guidance to deliver between $400 and $415 million in revenue with between 48% to 52% full year growth in exome and genome revenue**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Announced American Academy of Pediatrics (AAP) now recommends pediatricians use exome and genome testing as first-line for children with global developmental delay or intellectual disability**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Hosting conference call today at 8:30 a.m. ET**

**GAITHERSBURG, Md., July 29, 2025 —** GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the second quarter of 2025.

"Crossing the $100 million revenue mark and delivering our fourth consecutive profitable quarter is a major milestone for GeneDx, putting us on a path for more growth at scale and enabling us to reach more patients while reducing unnecessary spend across the global healthcare system," said Katherine Stueland, CEO of GeneDx. "Our strong second quarter performance was driven by our core business, underscoring its strength and resilience. These results, coupled with the ever-expanding opportunities ahead, including general pediatrics, demonstrate that we're just beginning to deliver on the promise of how our technology can fundamentally change the way genomics can inform healthcare, shifting from reactive to proactive care."

**Second Quarter 2025 Financial Results (Unaudited)**<sup>1,2</sup>

***Revenues***

&nbsp;&nbsp;&nbsp;&nbsp;• Revenues grew to $102.7 million, an increase of 49% year-over-year.

&nbsp;&nbsp;&nbsp;&nbsp;• Exome and genome test revenue grew to $85.9 million, an increase of 69% year-over-year.

***Exome and genome volume***

&nbsp;&nbsp;&nbsp;&nbsp;• Exome and genome test results volume grew to 23,102, an increase of 28% year-over-year.

&nbsp;&nbsp;&nbsp;&nbsp;• Exome and genome represented 41% of all tests, up from 31% in the second quarter of 2024.

***Gross margin***

&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted gross margin expanded to 71%, up from 62% in the second quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Total GAAP gross margin was 69%.

***Operating expenses***

&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted total operating expenses were $57.8 million, representing 56% of revenue in the second quarter of 2025, compared to 65% of revenue in the second quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Total GAAP operating expenses were $61.9 million.

***Net Income***

&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted net income was $15.0 million compared to an adjusted net loss of $2.0 million in the second quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ GAAP net income was $10.8 million.

------

***Cash position***

&nbsp;&nbsp;&nbsp;&nbsp;• Cash, cash equivalents, marketable securities and restricted cash was $135.5 million as of June 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;• Cash flow for the second quarter 2025 primarily included:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ $33.2 million used to acquire Fabric Genomics, net of cash acquired, partially offset by;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ $10.4 million in cash generated from operations.

&nbsp;&nbsp;&nbsp;&nbsp;1.Revenue and adjusted gross margin growth rates exclude revenue and costs of sales from the exited Legacy Sema4 diagnostic testing business.

&nbsp;&nbsp;&nbsp;&nbsp;2.Adjusted gross margin, adjusted total operating expenses and adjusted net income/(loss) are non-GAAP financial measures. See appendix for a reconciliation of GAAP to non-GAAP figures presented.

**GeneDx Full Year 2025 Guidance**

GeneDx has raised certain elements of its full year 2025 guidance and expects to deliver:

---

| | | |
|:---|:---|:---|
| **Metric** | **Previous Guidance** | **Updated Guidance** |
| Revenue | $360 to $375 million | $400 to $415 million |
| Growth in exome and genome revenue | 30% | 48% to 52% |
| Growth in exome and genome volume | 30% | 30% |
| Adjusted gross margin | 66% to 68% | 68% to 71% |
| Adjusted net income | Positive each quarter and for full year | Positive each quarter and for full year |

---

**Second Quarter 2025 and Recent Business Highlights**

*Strategic Expansion and Market Access* 

&nbsp;&nbsp;&nbsp;&nbsp;• Announced that the American Academy of Pediatrics now recommends exome and genome sequencing as first-tier tests for children with global developmental delay or intellectual disability, positioning pediatricians to offer exome and genome testing to their patients.

&nbsp;&nbsp;&nbsp;&nbsp;• Expanded commercial focus to include calling on providers treating children with inborn errors of immunity (IEI), a group of nearly 500 genetic disorders that impair immune function.

&nbsp;&nbsp;&nbsp;&nbsp;• Accelerated adoption of exome and genome sequencing coverage by state Medicaid programs, bringing the total states covering exome or genome sequencing in the pediatric outpatient setting to 35 with the recent addition of Colorado and Maine, and the total states covering rapid genome sequencing in the neonatal intensive care unit (NICU) to 17 with the recent addition of Virginia, Ohio, and Oklahoma.

*Innovation & Clinical Leadership* 

&nbsp;&nbsp;&nbsp;&nbsp;• Acquired Fabric Genomics, enabling a hybrid centralized and decentralized model for delivering genomic insights globally.

&nbsp;&nbsp;&nbsp;&nbsp;• Published SeqFirst study in the *Journal of Pediatrics*, showing rapid genomic testing reduced time to diagnosis from about 10 months to 13 days.

&nbsp;&nbsp;&nbsp;&nbsp;• Published data in the *American Journal of Medical Genetics* underscoring GeneDx's leadership in leveraging artificial intelligence (AI) to increase diagnostic yield and improve healthcare for patients with genetic conditions.

------

**Webcast and Conference Call Details**

GeneDx will host a conference call today, July 29, 2025, at 8:30 a.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/.

**Forward-Looking Statements**

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our future performance, future operations, plans, objectives of management, and our market opportunity, including our expected full year 2025 reported revenue, volume, adjusted gross margin and adjusted net income. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic direction, and (v) our ability to utilize our artificial intelligence tools that we use in our clinical interpretation platform. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" sections of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC") on February 20, 2025, and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, filed with the SEC on April 30, 2025 and July 29, 2025, respectively, and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.

**About GeneDx**

At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world's largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.

**Investor Relations Contact:**

Investors@GeneDx.com

**Media Contact:**

Press@GeneDx.com

------

**Volume & Revenue** <sup>1</sup>

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **2Q25** | **1Q25** | **4Q24** | **3Q24** | **2Q24** |
| **Volumes** | | | | | |
| Whole exome, whole genome | 23102 | 20562 | 20676 | 19262 | 18017 |
| Hereditary cancer | 2677 | 2725 | 3486 | 4672 | 5482 |
| Other panels | 29894 | 28228 | 30115 | 35095 | 34204 |
| Total | 55673 | 51515 | 54277 | 59029 | 57703 |
| **Revenue ($ millions)** |  |  |  |  |  |
| Whole exome, whole genome | $85.9 | $71.4 | $78.8 | $60.0 | $50.7 |
| Hereditary cancer | 1.8 | 2.2 | 2.8 | 3.3 | 3.8 |
| Other panels | 12.1 | 12.1 | 12.3 | 13.8 | 13.3 |
| Data information | 2.0 | 1.4 | 1.4 | (0.5) | 1.1 |
| Fabric Genomics | 0.9 |  |  |  |  |
| Total | $102.7 | $87.1 | $95.3 | $76.6 | $68.9 |

---

1. Excludes volume and revenue from the exited Legacy Sema4 diagnostic testing business.

**Unaudited Select Financial Information (in thousands)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended June 30, 2025** | **Three months ended June 30, 2025** | **Three months ended June 30, 2025** | **Three months ended June 30, 2024** | **Three months ended June 30, 2024** | **Three months ended June 30, 2024** |
| | **GeneDx** | **Other**<sup>1</sup> | **Total** | **GeneDx** | **Other**<sup>1</sup> | **Total** |
| Revenue | $101784 | $908 | $102692 | $68924 | $1590 | $70514 |
| Adjusted cost of services | 29964 | 244 | 30208 | 26523 | 145 | 26668 |
| Adjusted gross profit (loss) | $71820 | $664 | $72484 | $42401 | $1445 | $43846 |
| Adjusted gross margin % | 70.6% | 73.1% | 70.6% | 61.5% | 90.9% | 62.2% |

---

1. Other includes revenue and cost of services from the Legacy Sema4 diagnostic testing business for both periods presented. For the three months ended June 30, 2025, Other includes revenue and cost of services from Fabric Genomics.

------

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended June 30, 2025** | **Three months ended June 30, 2025** | **Three months ended June 30, 2025** | **Three months ended June 30, 2025** | **Three months ended June 30, 2025** | **Three months ended June 30, 2025** | **Three months ended June 30, 2025** |
| | **Reported** | **Depreciation and amortization** | **Stock-based compensation expense** | **Restructuring costs** | **Change in FV of financial liabilities** | **Other** | **Adjusted** |
| Diagnostic test revenue | $99823 | $— | $— | $— | $— | $— | $99823 |
| Other revenue | 2869 |  |  |  |  |  | 2869 |
| Total revenue | 102692 |  |  |  |  |  | 102692 |
| Cost of services | 31790 | (1389) | (193) |  |  |  | 30208 |
| Gross profit (loss) | 70902 | 1389 | 193 |  |  |  | 72484 |
| Gross margin | 69.0% |  |  |  |  |  | 70.6% |
| Research and development | 15079 | (209) | (1422) |  |  |  | 13448 |
| Selling and marketing | 19448 | (1298) | (1268) |  |  |  | 16882 |
| General and administrative | 27415 | (3295) | (4930) | (73) |  | 8342 | 27459 |
| Loss from operations | 8960 | 6191 | 7813 | 73 |  | (8342) | 14695 |
| Interest income (expense), net | (817) |  |  |  |  | 817 |  |
| Other income (expense), net | 2420 |  |  |  | (2181) | 49 | 288 |
| Income tax benefit | 246 |  |  |  |  | (246) |  |
| Net income | $10809 | $6191 | $7813 | $73 | $(2181) | $(7722) | $14983 |
| Basic earnings per share\* | $0.38 |  |  |  |  |  | $0.52 |
| Diluted earnings per share\* | $0.36 |  |  |  |  |  | $0.50 |

---

\*Basic and diluted earnings per share are calculated based on 28,579,704 and 29,753,933 weighted average shares outstanding for the three months ended June 30, 2025, respectively.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended June 30, 2024** | **Three months ended June 30, 2024** | **Three months ended June 30, 2024** | **Three months ended June 30, 2024** | **Three months ended June 30, 2024** | **Three months ended June 30, 2024** | **Three months ended June 30, 2024** |
| | **Reported** | **Depreciation and amortization** | **Stock-based compensation expense** | **Restructuring costs** | **Change in FV of financial liabilities** | **Other**<sup>1</sup> | **Adjusted** |
| Diagnostic test revenue | $69439 | $— | $— | $— | $— | $— | $69439 |
| Other revenue | 1075 |  |  |  |  |  | 1075 |
| Total revenue | 70514 |  |  |  |  |  | 70514 |
| Cost of services | 27562 | (808) | (86) |  |  |  | 26668 |
| Gross profit (loss) | 42952 | 808 | 86 |  |  |  | 43846 |
| Gross margin | 60.9% |  |  |  |  |  | 62.2% |
| Research and development | 10902 | (211) | (347) | (35) |  |  | 10309 |
| Selling and marketing | 16585 | (1225) | (368) | (63) |  |  | 14929 |
| General and administrative | 26044 | (2974) | (2307) | (150) |  |  | 20613 |
| Loss from operations | (10579) | 5218 | 3108 | 248 |  |  | (2005) |
| Interest income (expense), net | (894) |  |  |  |  | 894 |  |
| Other income (expense), net | (17890) |  |  |  | 4409 | 13450 | (31) |
| Income tax benefit | 190 |  |  |  |  | (190) |  |
| Net loss | $(29173) | $5218 | $3108 | $248 | $4409 | $14154 | $(2036) |
| Basic loss per share\* | $(1.10) |  |  |  |  |  | $(0.08) |
| Diluted loss per share\* | $(1.10) |  |  |  |  |  | $(0.08) |

---

\*Basic and diluted loss per share are calculated based on 26,617,955 diluted weighted average shares outstanding for the three months ended June 30, 2024.

1. Other represents interest expense, net, and income tax (expense) benefit for all periods presented. Other for the three months ended June 30, 2025 includes transaction costs related to the acquisition of Fabric Genomics. Other for the three months ended June 30, 2024 includes legal costs related to a legal settlement.

------

**GeneDx Holdings Corp.**

**Condensed Consolidated Balance Sheets**

**(in thousands, except share and per share amounts)**

---

| | | |
|:---|:---|:---|
| | **June 30, 2025 (Unaudited)** | **December 31, 2024** |
| **Assets:** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $74120 | $85212 |
| &nbsp;&nbsp;&nbsp;Marketable securities | 60438 | 55973 |
| &nbsp;&nbsp;&nbsp;Accounts receivable | 48028 | 37629 |
| &nbsp;&nbsp;&nbsp;Inventory, net | 11932 | 10650 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 10319 | 8504 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 204837 | 197968 |
| Operating lease right-of-use assets | 24978 | 25613 |
| Property and equipment, net | 40120 | 32893 |
| Goodwill | 12926 |  |
| Intangible assets, net | 176689 | 158600 |
| Other assets<sup>1</sup> | 4313 | 4306 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $463863 | $419380 |
| **Liabilities and Stockholders' Equity:** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | $49239 | $30983 |
| &nbsp;&nbsp;&nbsp;Short-term lease liabilities | 3083 | 3336 |
| &nbsp;&nbsp;&nbsp;Other current liabilities | 19084 | 20498 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 71406 | 54817 |
| Long-term debt, net of current portion | 51683 | 51913 |
| Long-term lease liabilities | 59619 | 60919 |
| Other liabilities | 3275 | 5519 |
| Deferred taxes | 747 | 965 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 186730 | 174133 |
| **Stockholders' Equity:** |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock |  |  |
| &nbsp;&nbsp;&nbsp;Class A common stock | 2 | 2 |
| Additional paid-in capital | 1624513 | 1596889 |
| Accumulated deficit | (1348194) | (1352474) |
| Accumulated other comprehensive income | 812 | 830 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 277133 | 245247 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $463863 | $419380 |

---

1. Other assets includes $990 thousand of restricted cash as of both June 30, 2025 and December 31, 2024.

------

**GeneDx Holdings Corp.**

**Condensed Consolidated Statements of Operations (Unaudited)**

**(in thousands, except share and per share amounts)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended June 30,** | **Three months ended June 30,** | **Six months ended June 30,** | **Six months ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Revenue |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Diagnostic test revenue | $99823 | $69439 | $185582 | $130543 |
| &nbsp;&nbsp;&nbsp;Other revenue | 2869 | 1075 | 4225 | 2393 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenue | 102692 | 70514 | 189807 | 132936 |
| Cost of services&nbsp;&nbsp;&nbsp;&nbsp; | 31790 | 27562 | 60429 | 52573 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 70902 | 42952 | 129378 | 80363 |
| Research and development | 15079 | 10902 | 27656 | 22469 |
| Selling and marketing | 19448 | 16585 | 37764 | 32670 |
| General and administrative | 27415 | 26044 | 59549 | 49463 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income (loss) from operations | 8960 | (10579) | 4409 | (24239) |
| Non-operating income (expenses), net |  |  |  |  |
| Change in fair value of warrants and contingent liabilities | 2181 | (4409) | 1081 | (10510) |
| &nbsp;&nbsp;&nbsp;Interest expense, net | (817) | (894) | (1457) | (1491) |
| &nbsp;&nbsp;&nbsp;Other income (expense), net | 239 | (13481) | 448 | (13444) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total non-operating income (expense), net | 1603 | (18784) | 72 | (25445) |
| Income (loss) before income taxes | 10563 | (29363) | $4481 | $(49684) |
| Income tax benefit (expense) | 246 | 190 | (201) | 272 |
| Net income (loss) | $10809 | $(29173) | $4280 | $(49412) |
| Weighted average shares outstanding of Class A common stock - Basic | 28579704 | 26617955 | 28365018 | 26340063 |
| Earnings (loss) per share, Class A common stock- Basic | $0.38 | $(1.10) | $0.15 | $(1.88) |
| Weighted average shares outstanding of Class A common stock - Diluted | 29753933 | 26617955 | 29642555 | 26340063 |
| Earnings (loss) per share, Class A common stock- Diluted | $0.36 | $(1.10) | $0.14 | $(1.88) |

---

------

**GeneDx Holdings Corp.**

**Condensed Consolidated Statements of Cash Flows (Unaudited)**

**(in thousands)**

---

| | | |
|:---|:---|:---|
| | **Six months ended June 30,** | **Six months ended June 30,** |
| | **2025** | **2024** |
| **Operating activities** |  |  |
| Net income (loss) | $4280 | $(49412) |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization expense | 11869 | 10466 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation expense | 11796 | 2657 |
| &nbsp;&nbsp;&nbsp;Change in fair value of warrants and contingent liabilities | (1081) | 10510 |
| &nbsp;&nbsp;&nbsp;Deferred tax expense (benefit) | 202 | (272) |
| &nbsp;&nbsp;&nbsp;Provision for excess and obsolete inventory | 123 | 109 |
| &nbsp;&nbsp;&nbsp;Legal reserves |  | 13450 |
| &nbsp;&nbsp;&nbsp;Change in third party payor reserves | 5014 | 1066 |
| &nbsp;&nbsp;&nbsp;Other | 1387 | 1738 |
| &nbsp;&nbsp;&nbsp;Change in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (9889) | 6622 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | (1404) | (1654) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | 7199 | (10871) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets and liabilities | (8894) | (5327) |
| Net cash provided by (used in) operating activities | 20602 | (20918) |
| **Investing activities** |  |  |
| Acquisition of business, net of cash acquired | (33195) |  |
| Purchases of property and equipment | (8498) | (1795) |
| Purchases of marketable securities | (30770) | (29381) |
| Proceeds from sales of marketable securities |  | 598 |
| Proceeds from maturities of marketable securities | 26705 | 8720 |
| Net cash used in investing activities | (45758) | (21858) |
| **Financing activities** |  |  |
| Proceeds from offerings, net of issuance costs | 13766 |  |
| Proceeds from issuance of common stock pursuant to employee stock purchase plan | 1262 |  |
| Exercise of stock options | 800 | 161 |
| Long-term debt principal payments | (602) |  |
| Finance lease principal payments | (1162) | (990) |
| Net cash provided by (used in) financing activities | 14064 | (829) |
| Net decrease in cash, cash equivalents and restricted cash  | (11092) | (43605) |
| Cash, cash equivalents and restricted cash, at beginning of period | 86202 | 100668 |
| Cash, cash equivalents and restricted cash, at end of period <sup>(1)</sup> | $75110 | $57063 |
| **Supplemental disclosures of cash flow information** |  |  |
| Cash paid for interest | $3210 | $4033 |
| Cash paid for taxes | $920 | $557 |
| Stock consideration paid pursuant to exercise of Perceptive warrant | $— | $12586 |
| Purchases of property and equipment in accounts payable and accrued expenses | $5752 | $501 |
| Assets acquired under capital lease obligations | $— | $689 |

---

(1)Cash, cash equivalents and restricted cash at June 30, 2025 excludes marketable securities of $60.4 million.

## Exhibit 99.2

![](finalq2earningspresentat001.jpg)

GeneDx (Nasdaq: WGS) 2Q 2025 Earnings Presentation July 29, 2025 Exhibit 99.2

------

![](finalq2earningspresentat002.jpg)

Confidential & Proprietary. Do Not Distribute. 2 Forward Looking Statements This presentation contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our future performance, future operations, plans, objectives of management, and our market opportunity, including our expected full year 2025 reported revenue, volume, adjusted gross margin and adjusted net income. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic direction, and (v) our ability to utilize our artificial intelligence tools that we use in our clinical interpretation platform. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" sections of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC") on February 20, 2025, and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, filed with the SEC on April 30, 2025 and July 29, 2025, respectively, and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations. We discuss these and other risks and uncertainties in greater detail in the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our periodic reports and other filings we make with the SEC from time to time. Given these uncertainties, you should not place undue reliance on the forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations. We file reports, proxy statements, and other information with the SEC. Such reports, proxy statements, and other information concerning us are available www.sec.gov. Requests for copies of such documents should be directed to our Investor Relations department at GeneDx Holdings Corp. 333 Ludlow Street, North Tower 6th Floor, Stamford, Connecticut, 06902. Our telephone number is 888-729-1206.

------

![](finalq2earningspresentat003.jpg)

Confidential & Proprietary. Do Not Distribute. 3 We envision a world where any genetic disorder is diagnosed as early as possible to prevent disease progression and ensure long and healthy lives for all.

------

![](finalq2earningspresentat004.jpg)

Confidential & Proprietary. Do Not Distribute. 4 X X X 1 year X X X 2 years X X X 3 years X X X 4 years X X X 5 years On average: 16 tests and 5 years before an accurate diagnosis We prevent the unnecessary diagnostic journey GeneDx provides answers in months weeks days hours References: 1. National Organization for Rare Disorders (NORD). Hope for Millions of Children Living With Rare Diseases. Retrieved from https://rarediseases.org/wp-content/uploads/2024/07/NORD-PRV-One- Pager.pdf 2. Willmen, T., Ronicke, S., Gabriel, H., & Wagner , A. D. (2023). Rare diseases: why is a rapid referral to an expert center so impor tant? . BMC Health Services Research, 23(1) , 904. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10463573/ 3.Marshall, D. A., & Spolador, G. (2021). The complexity of diagnosing rare disease: An organizing framework for outcomes research and health economics based on rea l-world evidence. Current Opinion in Structural B iology, 68, 1-9. Retrieved from https://www.sciencedirect.com/science/article/pii/S1098360021053831

------

![](finalq2earningspresentat005.jpg)

Confidential & Proprietary. Do Not Distribute. 5 We are the leader in diagnosing rare diseases First-mover advantage and durable market leadership Data unmatched in size, breadth, and depth • Enriched for rare disease Diagnosing even the rarest conditions for 25 years • 60% of exomes and genomes are parent/child trios Enabling de novo findings by sequencing asymptomatic parents • >7 million phenotypic datapoints Bridging clinical information and genomic insights • 10+ years of testing diverse patient populations Representing the full U.S. population diversity • All underpinned by expert annotation and curation Bringing accurate answers to more patients today • Leader in exome and genome testing Delivering more rare disease diagnoses than anyone else • Chosen 8 of 10 times by geneticists The lab of choice for genetics experts • #1 genetic testing brand Top brand amongst pediatric healthcare providers • Identified >500 new disease-gene relationships Contributing a better understanding of rare diseases

------

![](finalq2earningspresentat006.jpg)

Confidential & Proprietary. Do Not Distribute. 6 With every patient, we accelerate and widen our competitive advantage >850K exomes & genomes >7M phenotypic datapoints The compounding power of our data informs more diagnoses and extends our lead. Additional patients tested Improved interpretation platform More underlying data Higher diagnostic yield and more answers for more patients

------

![](finalq2earningspresentat007.jpg)

Confidential & Proprietary. Do Not Distribute. 7 We are increasing market adoption through breadth and depth Market Segment Number of Targets Patient Opportunity Current Market Penetration (Patients) Newborn Screening Up to 3,600, 0001 babies born in the US annually who could be eligible NICU 800 Level III and IV NICUs >235, 0002 3.7% Pediatricians 60,000 (25,000)3 >600, 0004 <1% Pediatric Immunologists 600 >25, 0005 0% Pediatric Neurologists 2,000 (1,700)6 >180, 0007 14%8 Geneticists 2,000 80%9 Adult Specialists Could represent ~5,100,00010 patients annually with a variety of conditions Increasing the total market opportunity available over time Complemented by biopharma business that opens new avenues for growth Total Future Market Opportunity Pediatrics & Rare ($25B) Adult ($20B) 1. Live births in the U.S. annually. 2. Based on total number of NICU beds (~27,600), average length of stay of 15 days, 24 patients per bed per year, 70% of beds are occupied and 50% of the patients receive testing. 3. Pediatricians who diagnose patients with DD/ID (ICD-10 codes) 4. Diagnoses of DD/ID by pediatricians (ICD-10 codes). 5. Claims and clinical data for patients with IEIs. 6. Pediatric neurologists seeing target patients (ICD-10 codes) 7. Patients with target conditions seen by pediatric neurologists, developmental specialists, and geneticists (ICD-10 codes). Due to referral patterns, we report one number for this group of clinicians. 8. Internal volume data for patients with target conditions. 9. Claims data 10. Adult patients that are good candidates for exome/genome with conditions such as cardiomyopathies, neurodegenerative disorders, etc. (ICD-10 codes) D ri v in g e a rl ie r d ia g n o s e s

------

![](finalq2earningspresentat008.jpg)

Confidential & Proprietary. Do Not Distribute. 8 Grew revenues to $102.7 million, an increase of 49%2 year-over-year Delivered adjusted gross margin of 71%, up from 62% in the second quarter of 2024 Grew exome and genome test revenue to $85.9 million, an increase of 69% year-over-year Generated adjusted net income of $15.0 million in the second quarter of 2025 1. Adjusted gross margin and adjusted net income are non-GAAP financial measures. See appendix for a reconciliation of GAAP to non-GAAP figures presented. 2. When compared to 2024 revenue from continuing operations, excluding the exited Legacy Sema4 business. Second Quarter 2025 Results1

------

![](finalq2earningspresentat009.jpg)

Confidential & Proprietary. Do Not Distribute. 9 41% • Grew Q2 2025 exome and genome volume 28% year-over-year • Grew mix share for exome and genome to 41% Strong exome and genome volume growth, picking up mix share 22% 31% 23,102 18,017 11,855 Quarterly Exome and Genome Volume Exome and Genome Volume Mix

------

![](finalq2earningspresentat010.jpg)

Confidential & Proprietary. Do Not Distribute. 10 Q4 2023 Q3 2024 Q4 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Delivered our fourth consecutive profitable quarter • Generated second quarter 2025 adjusted net income1 of $15.0 million • Delivered fourth consecutive quarter of adjusted net income1 and second quarter of positive operational cash flow • Cash, cash equivalents, marketable securities and restricted cash was $135.5 million as of June 30, 2025 1. Adjusted net income/(loss) is a non-GAAP financial measures. See appendix for a reconciliation of GAAP to non-GAAP figures presented. Q1 2025 Quarterly Adj. Net (Loss)/Income1 (in millions) Q2 2025

------

![](finalq2earningspresentat011.jpg)

Full Year 2025 Guidance 11 Metric Previous Guidance Updated Guidance Revenue $360 to $375 million $400 to $415 million Growth in exome and genome revenue 30% 48% to 52% Growth in exome and genome volume 30% 30% Adjusted gross margin 66% to 68% 68% to 71% Adjusted net income Positive each quarter and for full year Positive each quarter and for full year

------

![](finalq2earningspresentat012.jpg)

Confidential & Proprietary. Do Not Distribute. 12 The future of healthcare is about proactive, personalized care. GeneDx is leading the way.

------

![](finalq2earningspresentat013.jpg)

13 Confidential & Proprietary. Do Not Distribute. Appendix

------

![](finalq2earningspresentat014.jpg)

Confidential & Proprietary. Do Not Distribute. 14 Reconciliation of non-GAAP financial measures Adjusted gross profit and adjusted gross margin (in $ thousands) Three months ended June 30 2025 2024 GeneDx Other1 Total GeneDx Other1 Total Revenue $101,784 $908 $102,692 $68,924 $1,590 $70,514 Adjusted cost of services 29,964 244 30,208 26,523 145 26,668 Adjusted gross profit $71,820 $664 $72,484 $42,401 $1,445 $43,846 Adjusted gross margin 71% 71% 62% 62% Reconciliations: Depreciation and amortization 1,389 808 Stock-based compensation 193 86 Gross profit $70,902 $42,952 Gross margin 69% 61% (in $ thousands) Three months ended June 30, 2025 June 30, 2024 Net income (loss) $10,809 $(29,173) Reconciliations: Depreciation and amortization expense 6,191 5,218 Stock-based compensation expense 7,813 3,108 Restructuring costs 73 248 Change in fair value of financial liabilities (2,181) 4,409 Other1 (7,722) 14,154 Adjusted net income (loss) $14,983 $(2,036) Adjusted net income 1. For the three months ended June 30, 2025, represents interest expense, net, income tax expense, net, transaction costs associated with the Merger Agreement and a sales-and-use tax refund. For the three months ended June 30, 2024, represents interest expense, net, income tax benefit, net, and reserves net of insurance for a certain litigation matter. 1. Other includes revenue and cost of services from the Legacy Sema4 diagnostic testing business for both periods presented. For the three months ended June 30, 2025, Other includes revenue and cost of services from Fabric Genomics.

------